EP0222881A1 - Compositions antiacides a action prolongee - Google Patents

Compositions antiacides a action prolongee

Info

Publication number
EP0222881A1
EP0222881A1 EP86903790A EP86903790A EP0222881A1 EP 0222881 A1 EP0222881 A1 EP 0222881A1 EP 86903790 A EP86903790 A EP 86903790A EP 86903790 A EP86903790 A EP 86903790A EP 0222881 A1 EP0222881 A1 EP 0222881A1
Authority
EP
European Patent Office
Prior art keywords
long
antacid
acting
grams
dosage unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP86903790A
Other languages
German (de)
English (en)
Other versions
EP0222881A4 (fr
Inventor
Max A. Tesler
John D. Flanagan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacontrol Corp
Original Assignee
Pharmacontrol Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacontrol Corp filed Critical Pharmacontrol Corp
Publication of EP0222881A1 publication Critical patent/EP0222881A1/fr
Publication of EP0222881A4 publication Critical patent/EP0222881A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

Definitions

  • This invention relates to compositions that- can reduce gastric acidity for relatively long periods of time after administration. More particularly, the invention relates to novel combinations of acid-neutralizing compounds, dietary fiber and prostaglandin biosynthetic precursors. These compositions are in a highly palatable form and are useful ⁇ for the treatment or prevention of gastric hyperacidity and the discomfort and disease conditions that it can produce.
  • erythro 15, 16-dioxyprostanoic acids and esters [Weiss, U.S. Patent 4,113,967], 11 ⁇ -homo-prostanoic acid derivatives [Floyd, Jr. et al , ., U.S. Patent 3,985,798], 16,16-ethylene derivatives of prostaglandin E, and its homologues [Walker, U.S. Patent 4,039,654], and arachidonic acid [Konture et al., J. Physiol. 286;15 (1979); Conolly et al., Gut 1 :429 (1977)] have been shown to inhibit gastric acid secretion.
  • Arachidonic acid has been shown by Tarnawski et al. [J.
  • the present invention provides novel compositions for the prolonged reduction: of gastric acidity. This reduction
  • in gastric acidity is useful for the treatment or prevention o of a number of disorders caused by such acidity such as heartburn, epigastric buring pain, sour stomach, -indigestion, esophagitis, peptic ulcers and gastritis-duodenitis.
  • the prolonged gastric acid-reducing effects of the invention are achieved by novel combinations of one or more antacid compounds, a source of prostaglandin precursors and t dietary fiber. These components act in concert to counter gastric acidity: the antacid compound (or compounds) acts to neutralize the acidity, while the prostaglandin precursors and dietary fiber serve to delay gastric emptying, thereby prolonging the antacid action.
  • compositions of the invention may be added to the compositions of the invention.
  • mouth feel may be optimized by manipulation of the granularity of the ingredients of the compositions, particularly the dietary fiber component.
  • the compositons of the invention are incorporated into a solid wafer or cookie form. These dosage forms are
  • This invention relates to novel compositions containing one or more antacid compounds, a source of prostaglandin biosynthetic precursors and dietary fiber. Acting together, these components of the invention when administered orally produce a prolonged reduction in gastric acidity.
  • the invention further relates to compositions having other active components that can alleviate or reduce sources of discomfort that may accompany gastric hyperacidity or antacid treatment such as gas, constipation or generalized or 0 local pain.
  • the invention still further relates to compositions having coloring and/or flavoring agents that enhance palatability.
  • the antacid ingredients of the invention may be any nontoxic antacid compounds commonly used to neutralize gastric fluids.
  • Such compounds include but are not limited to aluminum carbonate; aluminum hydroxide; dihydroxyaluminum 0 aminoacetate; aluminum phosphate; dihydroxyaluminum sodium carbonate; sodium bicarbonate; bismuth aluminate, carbonate, subcarbonate, subgallate or subnitrate; calcium carbonate or phosphate; citric acid or its salts; magnesium aluminosilicates, carbonate, glycinate, hydroxide, oxide or trisilicate; mono-, di-' or tribasic calcium phosphate; potassium bicarbonate; sodium potassium tartrate; magnesium o hydroxyaluminates and aluminum oxyhydroxide or combinations thereof.
  • aluminum hydroxide and/or calcium carbonate are employed.
  • the quantity of antacid used per dosage unit may range from about 25 to about 95 milliequivalents ( Eq) of acid neutralizing capacity per dosage unit, with a preferred range of from about 60 to about 90 Eq.
  • the amount of calcium carbonate used per dosage unit may range from about 0.5 to about 4.0 grams, but preferably is in the range of from about 0.5 to about 2.0 grams.
  • aluminum hydroxide is the antacid a range of from about 0.6 to about
  • the acid neutralizing capacity of a sample can be determined by grinding the sample to a fine powder, mixing 10 grams of the power with 70 ml of deionized water, pipetting 25 mi of 1.0 N HCl into the solution and mixing for 15 minutes, and titrating the mixture with 1.0 N NaOH to pH 3.5.
  • the overall acid neutralizing capacity of a dosage unit is of course the product of the above value and the total weight of the dosage unit in grams.
  • a convenient dosage unit weights from about 26 to 31 grams, although of course other dosage sizes could be used instead.
  • the prostaglandin precursor source for the invention may be any material containing the polyunsaturated fatty acids that can be metabolized to the prostaglandins.
  • the principal fatty acids are arachidonic acid, which is metabolized to prostaglandins E., P 2 ⁇ - and G 2 , and eicosatrienoic acid, which is converted in the body to prostaglandin G1. Of these fatty acids, arachidonic acid is more important.
  • arachidonic acid either chemically synthesized or from natural sources, could be used. More economical and thus preferable sources are commercial lecithin, soybean oil or safflower oil. Safflower oil contains a mixture of fatty acids with varying chain lengths esterified to glycerol, as does soybean oil. In soybean oil there may also be up to 1% of free fatty acids not esterified to glycerol. Lecithin, which most often is produced commercially as a by-product in the manufacture of soybean oil is another good source of arachidonic acid.
  • the prostaglandin precursor is present as part of a mixture of the diglycerids of stearic, palmitic, oleic and longer chain fatty acids linked to the choline ester of phosphoric acid.
  • Commercial grade soybean lecithin contains about 5.5% C 20 to C 22 fatty acids, in which fraction arachidonic acid is found, and is a preferred source.
  • the quantity of lecithin per dosage unit may range from about 0.5 to about 3.0 grams, with from about 0.8 to about 1.3 grams preferred for a 26 to 31 gram dosage unit.
  • Soybean oil may be used as a source of prostaglandin precursors in a range from about 0.5 to about 3.0 grams, with from about 0.8 to about 1.3 grams preferred for a 26 to 31 gram dosage unit. Where safflower oil is used as the source of prostaglandin precursors, it may be present in an amount of from about 0.5 to about 3.0 grams, and preferably from about 0.8 to about 1.3 grams for a 26 to 31 gram dosage unit.
  • the fiber component of the invention is preferably of plant origin, although synthetic polymers having similar physicochemical properties could be used instead.
  • Potentially useful dietary fibers include hemicelluloses, pectins and lignin.
  • Convenient sources of fiber are wheat and corn bran, with corn bran being preferred.
  • the quantity of corn bran for a 26 to 31 gram dosage unit may range from about 6.0 to about 9.0 grams, with about 7.5 grams preferred.
  • two 26 to 31 gram dosage units are given containing together 170 mEq buffering capacity of a suitable antacid as described above,
  • Formulations for a cookie dosage form of the present invention may be seen in Table 1.
  • ammonium bicarbonate was dissolved in the water in a separate container and then added to the above mixed ingredients over a period of one minute while mixing at speed one.
  • the blended dough mixture was then formed into cookies in a (make and model) rotary machine and the cookies were baked at 400 * F for 10 to 11 minutes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des compositions à action prolongée de réduction de l'acidité gastrique comprennent un ou plusieurs composés antiacides, une source de précurseurs de prostaglandine et des fibres alimentaires.
EP19860903790 1985-05-10 1986-05-09 Compositions antiacides a action prolongee. Withdrawn EP0222881A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73278485A 1985-05-10 1985-05-10
US732784 1996-10-15

Publications (2)

Publication Number Publication Date
EP0222881A1 true EP0222881A1 (fr) 1987-05-27
EP0222881A4 EP0222881A4 (fr) 1987-09-02

Family

ID=24944944

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860903790 Withdrawn EP0222881A4 (fr) 1985-05-10 1986-05-09 Compositions antiacides a action prolongee.

Country Status (3)

Country Link
EP (1) EP0222881A4 (fr)
DK (1) DK10387A (fr)
WO (1) WO1986006632A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2346646A1 (fr) * 1998-10-06 2000-04-13 Mars Uk Limited Stereotypie chez l'animal
GB2358136A (en) * 2000-01-15 2001-07-18 Univ Montfort A medicament for the treatment of equine oral stereotypies using a pH regulator
US20110195130A1 (en) * 2010-02-09 2011-08-11 Sanford Siegal Edible compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB190826894A (en) * 1908-12-11 1909-08-19 Thomson Bennett Ltd Improvements relating to Electric Ignition Apparatus for Internal Combustion Engines.
US2061184A (en) * 1931-04-10 1936-11-17 Curtis B Camp Food product
US2638433A (en) * 1949-11-17 1953-05-12 James T George Pharmaceutical preparation for peptic ulcers
US3019109A (en) * 1960-05-10 1962-01-30 American Cyanamid Co Stabilization of antibiotics in feeds and feed supplements
US3253988A (en) * 1962-11-20 1966-05-31 Robert I Pearlman Antacid composition and method of using same
US3843778A (en) * 1970-04-28 1974-10-22 Rorer Inc William H Antacids
US4542019A (en) * 1983-03-11 1985-09-17 John Lezdey Antacid compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No relevant documents have been disclosed. *
See also references of WO8606632A1 *

Also Published As

Publication number Publication date
EP0222881A4 (fr) 1987-09-02
DK10387D0 (da) 1987-01-09
DK10387A (da) 1987-03-09
WO1986006632A1 (fr) 1986-11-20

Similar Documents

Publication Publication Date Title
US5229137A (en) Methods and pharmaceutical compositions for treating episodic heartburn
US4895723A (en) Cholestyramine compositions and method for preparation thereof
US4650669A (en) Method to make effervescent calcium tablets and calcium tablets produced thereby
DE3406127C2 (fr)
EP0428296B1 (fr) Compositions pharmaceutiques pour le traitement de problèmes gastro-intestinaux
EP0492235B1 (fr) Composition à faible taux d'humidité à base de cholestyramine
US3253988A (en) Antacid composition and method of using same
WO1991000096A1 (fr) Aspirine a dissolution dans la cavite sublinguale et a dosage faible
US5686107A (en) Chewable pharmaceutical tablets
US3257275A (en) Chitosan containing antacid composition and method of using same
CA1207239A (fr) Compose gastro-intestinal
EP0578732B1 (fr) Compositions antacides a macher
KR100263284B1 (ko) 활성성분으로서의 디클로로메틸렌디포스폰산을 함유하는 생체 이용률이 개선된 정제
US4704278A (en) Fluidized magaldrate suspension
JPH06506682A (ja) 上部胃腸管症状を治療するための内服医薬組成物
US4476121A (en) Bowel evacuant and method of treating constipation
WO1990007343A1 (fr) Compositions liquides a base d'huiles comestibles pour administration par voie orale
CN1132070A (zh) 药用的水悬浮液制剂
US3577533A (en) Antacid compositions containing bismuth aluminate and coprecipitated aluminum hydroxide and magnesium carbonate
EP0222881A1 (fr) Compositions antiacides a action prolongee
EP0022429A1 (fr) Procédé de préparation d'agents de neutralisation de l'acide gastrique et les agents de neutralisation de l'acide gastrique
US4539315A (en) Sublingually absorbable nontoxic aspirin composition
JPH06502855A (ja) 抗ヒスタミンｈ↓２受容体拮抗剤および生体接着剤を含有する組成物
US3485920A (en) Analgesic compositions of aspirin and pectin
EP0320519B1 (fr) Compositions de cholestyramine et leur méthode de préparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19870123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19870902

17Q First examination report despatched

Effective date: 19890519

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19890930

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TESLER, MAX, A.

Inventor name: FLANAGAN, JOHN, D.